Supernus Pharmaceuticals reported $226.8M in Sales Revenues for its fiscal quarter ending in September of 2026.





Sales Change Date
Abbott USD 13.01B 423M Sep/2026
ANI Pharmaceuticals USD 290.77M 24.77M Sep/2026
Aurora Cannabis CAD 67.55M 29.54M Jun/2026
Bristol-Myers Squibb USD 13.07B 100M Sep/2026
Canopy Growth CAD 81.16M 9.91M Jun/2026
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Corcept Therapeutics USD 340.5M 84.35M Sep/2026
Eisai JPY 235.63B 1.3B Sep/2026
Eli Lilly USD 24.4B 1.43B Sep/2026
Novo Nordisk DKK 78.49B 18.33B Jun/2026
Pacira USD 176.65M 15.75M Sep/2026
Perrigo USD 989M 31M Sep/2026
Pfizer USD 16.6B 1.57B Sep/2026
Supernus Pharmaceuticals USD 226.8M 7.7M Sep/2026
United Therapeutics USD 832.5M 49.2M Sep/2026
Xeris Pharmaceuticals USD 92.1M 8.97M Jun/2026